StreetInsider.com News Articles

Form 4 Eton Pharmaceuticals, For: Aug 28 Filed by: MAIER PAUL V

Fri, 28 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260828/26998791.html

Form 4 Eton Pharmaceuticals, For: Aug 28 Filed by: MAIER PAUL V

Fri, 28 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260828/26998791.html

Form 144 Eton Pharmaceuticals, Filed by: MAIER PAUL V

Fri, 28 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260828/26998684.html

Form 144 Eton Pharmaceuticals, Filed by: MAIER PAUL V

Fri, 28 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260828/26998684.html

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

Thu, 27 Aug 2026 06:50:00 -0400

DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10, 2026 in Boston, MA.

To schedule a 1x1 meeting with the Company, please contact your Wells Fargo institutional sales representative.

About Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

Thu, 27 Aug 2026 06:50:00 -0400

To schedule a 1x1 meeting with the Company, please contact your Wells Fargo institutional sales representative.

About Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments

Form 4 Eton Pharmaceuticals, For: Aug 24 Filed by: Krempa David

Mon, 24 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260824/26969165.html

Form 4 Eton Pharmaceuticals, For: Aug 24 Filed by: Krempa David

Mon, 24 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260824/26969165.html

Form 144 Eton Pharmaceuticals, Filed by: Krempa David

Mon, 24 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260824/26968364.html

Form 144 Eton Pharmaceuticals, Filed by: Krempa David

Mon, 24 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260824/26968364.html

Form 4 Eton Pharmaceuticals, For: Aug 19 Filed by: BRYNJELSEN SEAN

Thu, 20 Aug 2026 18:26:00 -0400

si-local-file:///var/storage/secattach/20260820/26957388.html

Form 4 Eton Pharmaceuticals, For: Aug 19 Filed by: BRYNJELSEN SEAN

Thu, 20 Aug 2026 18:26:00 -0400

si-local-file:///var/storage/secattach/20260820/26957388.html

Form 144/A Eton Pharmaceuticals, Filed by: BRYNJELSEN SEAN

Thu, 20 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260820/26957071.html

Form 144/A Eton Pharmaceuticals, Filed by: BRYNJELSEN SEAN

Thu, 20 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260820/26957071.html

Form 144 Eton Pharmaceuticals, Filed by: BRYNJELSEN SEAN

Wed, 19 Aug 2026 10:50:00 -0400

si-local-file:///var/storage/secattach/20260819/26948550.html

Form 144 Eton Pharmaceuticals, Filed by: BRYNJELSEN SEAN

Wed, 19 Aug 2026 10:50:00 -0400

si-local-file:///var/storage/secattach/20260819/26948550.html

Eton Pharmaceuticals (ETON) PT Raised to $70 at B.Riley

Fri, 14 Aug 2026 08:29:28 -0400

B.Riley analyst Madison El-Saadi raised the price target on Eton Pharmaceuticals (NASDAQ: ETON) to $70.00 (from $40.00) while maintaining a Buy rating.

Eton Pharmaceuticals (ETON) PT Raised to $70 at H.C. Wainwright

Fri, 14 Aug 2026 06:49:27 -0400

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Eton Pharmaceuticals (NASDAQ: ETON) to $70.00 (from $65.00) while maintaining a Buy rating.

After-Hours Movers: AMAT, DLO, GLOB, YSS, ETON

Thu, 13 Aug 2026 16:30:42 -0400

After-Hours Movers:

Applied Materials (NASDAQ: AMAT)

Applied Materials shares dipped 4% in a "sell-the-news" reaction despite delivering a solid fiscal Q3 beat-and-raise. The semiconductor equipment leader posted record Q3 revenue of $9.12 billion and EPS of $3.50, while issuing upbeat Q4 revenue guidance of $9.75–$10.75 billion (well above the $9.54 billion Wall Street consensus). Despite AI-driven materials engineering demand driving record performance, high expectations following a recent sector rally prompted short-term profit-taking.